Private Equity–Backed Faculty Employment and Emergency Medicine Board Examination Performance - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Private Equity–Backed Faculty Employment With Emergency Medicine Board Exam Performance

  • By

  • Emily Shearer

  • Samantha Palacios

  • Ryan Cassandra Burke

  • Yashaswini Singh

  • Andrew M. Ryan

  • Laura G. Burke

  • November 10, 2026

Share

  • 1

    Among 267 US emergency medicine residency programs, 70 (26.2%) employed faculty through private equity–backed physician groups.

  • 2

    Private equity–backed programs were more often community based and founded after 2015, and less often located at level 1 trauma centers.

  • 3

    Unadjusted written qualifying examination pass rates were lower in private equity–backed programs than in other programs (81.6% vs 89.6%).

  • 4

    After adjustment for program and emergency department characteristics, private equity backing was not significantly associated with written or oral board examination outcomes.

  • 5

    The observational study was limited by the use of board examination results as a proxy for educational quality.

Original Source(s)

Private Equity–Backed Faculty Employment and Emergency Medicine Board Examination Performance

  • by Emily Shearer, Samantha Palacios, Ryan Cassandra Burke, Yashaswini Singh, Andrew M. Ryan, Laura G. Burke

  • November 10, 2026

Related Content

Early doxycycline use may raise pregnancy loss risk

Investigators found higher pregnancy loss rates compared with alternative antibiotics for respiratory infections, although findings among patients with acne differed across databases.

Musings from The Power List: Henry Day

Analytical scientists are helping sequencing move from faster, cheaper measurements toward richer biological insights

  • November 9, 2026

  • 5 min
FDA Updates Potency Rules for Cell and Gene Therapies

Replacing guidance from 2011, the FDA's updated framework emphasizes potency assurance throughout cell and gene therapy development and manufacturing

  • November 11, 2026

  • 3 min